R&D
Novartis and Bristol Myers Pause Autoimmune CAR-T Trials Over Safety Signals
Just as cell therapy shows promise against autoimmune disease, cases of a rare, potentially life-threatening immune reaction have prompted two drugmakers to hit pause.